US Bio Company CEO Cashes Out 17 Billion Won in Company Shares Over Two Weeks

Liquidia Corp (NASDAQ: LQDA) CEO Roger Jeffs sold 75,000 shares of the company’s common stock on the open market on each of three occasions between May 8 and May 20, 2026, under a pre-established Rule 10b5-1 trading plan—totaling 225,000 shares. The stock traded between approximately $41.50 and $61.30 per share, generating roughly $12.6 million in gross proceeds (about KRW 17 billion). After these sales, Jeffs still holds over one million shares—directly and indirectly—along with unvested RSUs.

In a filing today, Liquidia announced that it will be added to the S&P SmallCap 600 index on June 22. In its Q1 2026 earnings report released May 11, the company achieved a year-over-year swing from a loss to a profit, driven by increased sales of its new drug.
()

Liquidia is a U.S. biotech company developing and commercializing treatments for rare cardiopulmonary diseases, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its inhaled treprostinil product, Yutrepia, received FDA approval in 2025 and began commercial shipments in June of that year, providing a strong growth catalyst.
()